A 52-week extension study showed that the drug continues to maintain favorable body composition with no safety issues.
As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions. The European Medicines Agency’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results